Form 4: Treace Medical Concepts Director James Treace Sells Shares Under 10b5-1 Plan

Director James Treace sold shares of Treace Medical Concepts (TMCI) on November 15, 2022, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• James Treace, a director at Treace Medical Concepts, sold a total of 49,000 shares of common stock on November 15, 2022.
• The sales were executed under a Rule 10b5-1 trading plan.
• The transactions occurred at varying weighted average prices: 46,500 shares at $20.12, 1,600 shares at $21.1813, 200 shares at $21.97, and 1,700 shares at $24.0167.
• Following the reported transactions, James Treace directly owns 1,036,441 shares and indirectly owns 556,183 shares through his spouse.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of insider trading under a pre-arranged plan, so it doesn't necessarily indicate positive or negative sentiment about the company's future.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives and directors to sell shares under pre-arranged trading plans to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates